116 related articles for article (PubMed ID: 21689933)
1. Aryl 1,4-diazepane compounds as potent and selective CB2 agonists: optimization of drug-like properties and target independent parameters.
Zindell R; Walker ER; Scott J; Amouzegh P; Wu L; Ermann M; Thomson D; Fisher MB; Fullenwider CL; Grbic H; Kaplita P; Linehan B; Patel M; Patel M; Löbbe S; Block S; Albrecht C; Gemkow MJ; Shih DT; Riether D
Bioorg Med Chem Lett; 2011 Jul; 21(14):4276-80. PubMed ID: 21689933
[TBL] [Abstract][Full Text] [Related]
2. 1,4-Diazepane compounds as potent and selective CB2 agonists: optimization of metabolic stability.
Riether D; Wu L; Cirillo PF; Berry A; Walker ER; Ermann M; Noya-Marino B; Jenkins JE; Albaugh D; Albrecht C; Fisher M; Gemkow MJ; Grbic H; Löbbe S; Möller C; O'Shea K; Sauer A; Shih DT; Thomson DS
Bioorg Med Chem Lett; 2011 Apr; 21(7):2011-6. PubMed ID: 21354795
[TBL] [Abstract][Full Text] [Related]
3. Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity.
Ermann M; Riether D; Walker ER; Mushi IF; Jenkins JE; Noya-Marino B; Brewer ML; Taylor MG; Amouzegh P; East SP; Dymock BW; Gemkow MJ; Kahrs AF; Ebneth A; Löbbe S; O'Shea K; Shih DT; Thomson D
Bioorg Med Chem Lett; 2008 Mar; 18(5):1725-9. PubMed ID: 18255291
[TBL] [Abstract][Full Text] [Related]
4. Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds.
Riether D; Zindell R; Wu L; Betageri R; Jenkins JE; Khor S; Berry AK; Hickey ER; Ermann M; Albrecht C; Ceci A; Gemkow MJ; Nagaraja NV; Romig H; Sauer A; Thomson DS
Bioorg Med Chem Lett; 2015 Feb; 25(3):581-6. PubMed ID: 25556092
[TBL] [Abstract][Full Text] [Related]
5. Discovery and optimization of novel purines as potent and selective CB2 agonists.
Hollinshead SP; Astles PC; Chambers MG; Johnson MP; Palmer J; Tidwell MW
Bioorg Med Chem Lett; 2012 Aug; 22(15):4962-6. PubMed ID: 22765893
[TBL] [Abstract][Full Text] [Related]
6. Selective CB2 receptor agonists. Part 3: the optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model.
Bartolozzi A; Cirillo PF; Berry AK; Hickey ER; Thomson DS; Wu L; Zindell R; Albrecht C; Ceci A; Gemkow MJ; Nagaraja NV; Romig H; Sauer A; Riether D
Bioorg Med Chem Lett; 2015 Feb; 25(3):587-92. PubMed ID: 25575658
[TBL] [Abstract][Full Text] [Related]
7. Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists.
Chu GH; Saeui CT; Worm K; Weaver DG; Goodman AJ; Broadrup RL; Cassel JA; DeHaven RN; LaBuda CJ; Koblish M; Brogdon B; Smith S; Le Bourdonnec B; Dolle RE
Bioorg Med Chem Lett; 2009 Oct; 19(20):5931-5. PubMed ID: 19736007
[TBL] [Abstract][Full Text] [Related]
8. Selective CB2 receptor agonists. Part 1: the identification of novel ligands through computer-aided drug design (CADD) approaches.
Hickey ER; Zindell R; Cirillo PF; Wu L; Ermann M; Berry AK; Thomson DS; Albrecht C; Gemkow MJ; Riether D
Bioorg Med Chem Lett; 2015 Feb; 25(3):575-80. PubMed ID: 25556098
[TBL] [Abstract][Full Text] [Related]
9. Optimisation of a novel series of selective CNS penetrant CB(2) agonists.
Watson C; Owen DR; Harding D; Kon-I K; Lewis ML; Mason HJ; Matsumizu M; Mukaiyama T; Rodriguez-Lens M; Shima A; Takeuchi M; Tran I; Young T
Bioorg Med Chem Lett; 2011 Jul; 21(14):4284-7. PubMed ID: 21669533
[TBL] [Abstract][Full Text] [Related]
10. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
Cheng Y; Albrecht BK; Brown J; Buchanan JL; Buckner WH; DiMauro EF; Emkey R; Fremeau RT; Harmange JC; Hoffman BJ; Huang L; Huang M; Lee JH; Lin FF; Martin MW; Nguyen HQ; Patel VF; Tomlinson SA; White RD; Xia X; Hitchcock SA
J Med Chem; 2008 Aug; 51(16):5019-34. PubMed ID: 18680277
[TBL] [Abstract][Full Text] [Related]
11. Decahydroquinoline amides as highly selective CB2 agonists: role of selectivity on in vivo efficacy in a rodent model of analgesia.
Manley PJ; Zartman A; Paone DV; Burgey CS; Henze DA; Della Penna K; Desai R; Leitl MD; Lemaire W; White RB; Yeh S; Urban MO; Kane SA; Hartman GD; Bilodeau MT; Trotter BW
Bioorg Med Chem Lett; 2011 Apr; 21(8):2359-64. PubMed ID: 21420857
[TBL] [Abstract][Full Text] [Related]
12. Imidazopyridine CB2 agonists: optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy.
Trotter BW; Nanda KK; Burgey CS; Potteiger CM; Deng JZ; Green AI; Hartnett JC; Kett NR; Wu Z; Henze DA; Della Penna K; Desai R; Leitl MD; Lemaire W; White RB; Yeh S; Urban MO; Kane SA; Hartman GD; Bilodeau MT
Bioorg Med Chem Lett; 2011 Apr; 21(8):2354-8. PubMed ID: 21420860
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
Diaz P; Xu J; Astruc-Diaz F; Pan HM; Brown DL; Naguib M
J Med Chem; 2008 Aug; 51(16):4932-47. PubMed ID: 18666769
[TBL] [Abstract][Full Text] [Related]
14. 5-Sulfonyl-benzimidazoles as selective CB2 agonists.
Verbist BM; De Cleyn MA; Surkyn M; Fraiponts E; Aerssens J; Nijsen MJ; Gijsen HJ
Bioorg Med Chem Lett; 2008 Apr; 18(8):2574-9. PubMed ID: 18394887
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships of 2,4-diphenyl-1H-imidazole analogs as CB2 receptor agonists for the treatment of chronic pain.
Yang SW; Smotryski J; Matasi J; Ho G; Tulshian D; Greenlee WJ; Brusa R; Beltramo M; Cox K
Bioorg Med Chem Lett; 2011 Jan; 21(1):182-5. PubMed ID: 21115245
[TBL] [Abstract][Full Text] [Related]
16. Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors.
Pasquini S; De Rosa M; Ligresti A; Mugnaini C; Brizzi A; Caradonna NP; Cascio MG; Bolognini D; Pertwee RG; Di Marzo V; Corelli F
Eur J Med Chem; 2012 Dec; 58():30-43. PubMed ID: 23085772
[TBL] [Abstract][Full Text] [Related]
17. Novel sulfamoyl benzamides as selective CB(2) agonists with improved in vitro metabolic stability.
Sellitto I; Le Bourdonnec B; Worm K; Goodman A; Savolainen MA; Chu GH; Ajello CW; Saeui CT; Leister LK; Cassel JA; Dehaven RN; Labuda CJ; Koblish M; Little PJ; Brogdon BL; Smith SA; Dolle RE
Bioorg Med Chem Lett; 2010 Jan; 20(1):387-91. PubMed ID: 19919895
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel cannabinoid receptor ligands by a virtual screening approach: further development of 2,4,6-trisubstituted 1,3,5-triazines as CB2 agonists.
Yrjölä S; Kalliokoski T; Laitinen T; Poso A; Parkkari T; Nevalainen T
Eur J Pharm Sci; 2013 Jan; 48(1-2):9-20. PubMed ID: 23131798
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists.
Behrenswerth A; Volz N; Toräng J; Hinz S; Bräse S; Müller CE
Bioorg Med Chem; 2009 Apr; 17(7):2842-51. PubMed ID: 19278853
[TBL] [Abstract][Full Text] [Related]
20. Microwave-assisted synthesis of quinoline, isoquinoline, quinoxaline and quinazoline derivatives as CB2 receptor agonists.
Saari R; Törmä JC; Nevalainen T
Bioorg Med Chem; 2011 Jan; 19(2):939-50. PubMed ID: 21215643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
